以上内容来自Benzinga Earnings专栏,原文如下:
- Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)
- Strong year-end cash position of €168.3 million
- Substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025
- 2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn